Pharmacokinetics and Absolute Bioavailability of Selegiline Following Treatment of Healthy Subjects With the Selegiline Transdermal System (6 mg/24 h): A Comparison With Oral Selegiline Capsules-Reference-Cited by-同舟云学术

Pharmacokinetics and Absolute Bioavailability of Selegiline Following Treatment of Healthy Subjects With the Selegiline Transdermal System (6 mg/24 h): A Comparison With Oral Selegiline Capsules

Published:2007-10 Issue:10 Volume:47 Page:1256-1267
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Azzaro Albert J.,Ziemniak John,Kemper Eva,Campbell Bryan J.,VanDenBerg Chad

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference33 articles.

1. Monoamine oxidase: from physiology and pathology to the design and clinical application of reversible inhibitors;Benedetti;Adv Drug Res.,1992

2. Selegiline: a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease;Chrisp;Drugs Aging,1991

3. The pharmacology of (-)deprenyl;Knoll;J Neural Transm Suppl,1986

4. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the ‘cheese effect’;Elsworth;Psychopharmacology,1978

5. Tyramine infusions and selective monoamine oxidase inhibitor treatment: I. Changes in pressor sensitivity;Pickar;Psychopharmacology,1981

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Altered states, alkaloids, and catatonia: Monoaminoxidase inhibitors and their role in the history of psychopharmacology;Frontiers in Pharmacology;2022-12-06

2. Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies;International Journal of Molecular Sciences;2022-09-21

3. Imaging of Reactive Astrogliosis by Positron Emission Tomography;Frontiers in Neuroscience;2022-02-08

4. Exosomes in Parkinson: Revisiting Their Pathologic Role and Potential Applications;Pharmaceuticals;2022-01-07

5. Monoamine Oxidase Inhibitors in Depressive Disorders;NeuroPsychopharmacotherapy;2022